Cue Biopharma, Inc. (NASDAQ: CUE) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.29 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 31.03%. A quarter ago, it was expected that this company would post a loss of $0.30 per share when it actually produced a loss of $0.25, delivering a surprise of 16.67%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. Cue Biopharma, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $2.66 million for the quarter ended June 2024, surpassing the Zacks Consensus Estimate by 137.96%. This compares to year-ago revenues of $1.38 million. The company has topped consensus revenue estimates three times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on ...